Rationale for aggressive lipid lowering in high-risk patients

Area of Science:

• Cardiology
• Lipid Metabolism

Background:

• Current National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines recommend LDL-C <100 mg/dL for high-risk patients.
• Optional NCEP ATP III target is LDL-C <70 mg/dL.
• Emerging data suggest physiologically normal LDL-C levels are lower, potentially impacting atherogenesis.

Purpose of the Study:

• To review current LDL-C targets and recent findings on lipid-lowering therapy.
• To discuss the implications of new data for future NCEP ATP IV guidelines.

Main Methods:

• Review of current NCEP ATP III guidelines (2002, updated 2004).
• Analysis of recent data on LDL-C lowering and its association with CHD events.
• Discussion of available pharmacologic options for LDL-C reduction.

Main Results:

• LDL-C lowering demonstrably reduces CHD events, irrespective of prior CHD status.
• Existing NCEP ATP III guidelines may not fully incorporate the latest evidence on intensive lipid management.

Conclusions:

• Intensive lipid-lowering therapy shows significant benefits in reducing CHD events.
• Future NCEP ATP IV guidelines are anticipated to address more recent findings on optimal LDL-C targets.